The problem for us is that Horst has been stumbling with investor questions for as long as I have owned IGXT.
Horst should stay in the lab and be paid a king's ransom and let an investment professional do the interviews.
I am constantly amazed by how quickly the investors on this board are willing to sell IGXT short in terms of market value.
My view is this:
We have a product which can be used with most oral medications, which could extend a patent term, and/or make a generic more effective.
There is roughly 70MM shares outstanding.
At $3/share, we are worth $210MM.
How much PFE, MRK, or another big pharma company pay for a product which could extend the patent life of a blockbuster drug.
Certainly not $210MM or even $2.1B. I think that the number is closer to $10B.
WAB has no interest in RAD as this would be strictly an exercise in store closures given the existing geographic overlap.
The most logical acquirer are of RAD are either MCK or ESRX as RAD fills a hole in their product lineups relative to CVS and WAB.
100x the current stock price makes sense to me.
But even at $5 billion, the acquirer would still be getting a sweetheart deal.
Based on your list, it seems to me that PSDV will hit at least $20/share by June.
Let's hope that the new on Tethadur is positive and that Roche wants to get into biologics like PFE did.
I would be a very happy person if PSDV's MV was 50% of HSP's by December 31, 2015.
Anything is possible.
Hopefully, our management is strong enough to not to sell out at a substandard price.
I think that like me, Mick is tired off being strung along by Dr. Paul.
I am curious to know what the sell-side is forecasting PSDV's 'earnings' will be.
It is a timing issue.
PSDV's cash at Dec. 31 will be much higher - otherwise we all have a lot to worry about.
The problem with PSDV rests squarely on the shoulders of Dr. Paul.
There is no question of his scientific intellect but as a CEO, well, he sucks.
Aside from developing the business strategy to move the company forward, a CEO must be able to effectively communicate to different market constituencies - specifically sell-side equity analysts and institutional/individual investors.
Here, he has failed badly. It is clear that he has a passion for the science but I get the sense that equity investors are of lesser concern to him.
Moreover, I am so tired hearing how management is conservative in how the company operates and communicates information. PSDV needs to toot its horn once in awhile as full time conservatism is a one-way trip to marginalization.